Key points:
INmune Bio, Quantum Computing to collaborate on XPro Alzheimer's treatment
DisclaimerContent provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or…
TradingView
Publisher
Oct 14, 2026 at 2:54 PM UTC · Updated vor 2 Tagen · 1 Min. Lesezeit
- INmune Bio and Quantum Computing will work together to advance the former's Alzheimer's disease candidate XPro1595 (XPro) and find potential new indications for the asset.
- The collaboration will focus on using quantum computing, AI, and data analytics.
- XPro is a dominant-negative tumor necrosis factor platform "designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function," according to INmune Bio.
- Using quantum computing, AI, and conventional data analytics, the companies intend to "uncover relationships that could help find diseases driven by the same biology XPro targets, and to prioritize those with the greatest potential for success."
- The deal marks Quantum Computing's first commercial customer in the pharmaceutical and biotechnology industries.
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.
Sourced by
Originally reported by TradingView
NewsLayer coverage based on externally reported material.
The Daily Brief
The onchain economy, before your day starts.
Curated markets, onchain insights, and key headlines — delivered every weekday morning.
Weekdays · Free · ~5 minute read
0
Applause
Was this article helpful?
Article Intelligence
Sponsored
Ad
NewsLayerLearn more
NewsLayer Premium
Unlock deeper intelligence.
Ad-free reading, exclusive research, and real-time onchain insights.
Go Premium
